Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Biochemical Recurrence”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Not applicableEnded earlyNCT04234399
What this trial is testing

Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy

Who this might be right for
Prostatic Neoplasm
University of Vermont 22
Not applicableUnknownNCT01530295
What this trial is testing

Biochemical Recurrence Rate of Radical Prostatectomy Combined With Neoadjuvant and Adjuvant Chemotherapy in High Risk Prostate Cancer

Who this might be right for
Prostate Cancer
Hanjong Ahn 70
Not applicableStudy completedNCT01347476
What this trial is testing

Aggressive Prostate Cancers in Elderly Patients

Who this might be right for
Prostatic Neoplasms
Seoul National University Hospital 1,333
Early research (Phase 1)Looking for participantsNCT05997615
What this trial is testing

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Who this might be right for
Hormone-refractory Prostate Cancer
Vir Biotechnology, Inc. 390
Testing effectiveness (Phase 2)Ended earlyNCT01531205
What this trial is testing

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

Who this might be right for
Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute 2
Large-scale testing (Phase 3)UnknownNCT00764166
What this trial is testing

A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel

Who this might be right for
Adenocarcinoma of the Prostate
Assistance Publique - Hôpitaux de Paris 254
Testing effectiveness (Phase 2)Active Not RecruitingNCT03444844
What this trial is testing

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

Who this might be right for
Prostate Cancer RecurrentProstate Cancer
Five Eleven Pharma, Inc. 60
Large-scale testing (Phase 3)Looking for participantsNCT06952803
What this trial is testing

Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Who this might be right for
Prostate Cancer
AstraZeneca 700
Not applicableUnknownNCT04870567
What this trial is testing

HDR Brachytherapy vs SABR in Early-intermediate Prostate Cancer

Who this might be right for
Biochemical Relapse Free SurvivalComplications Rates (Erectile Dysfunction, GI, GU Complications)
N.N. Petrov National Medical Research Center of Oncology 350
Testing effectiveness (Phase 2)Looking for participantsNCT04700332
What this trial is testing

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Who this might be right for
Prostate Cancer
Hoag Memorial Hospital Presbyterian 184
Large-scale testing (Phase 3)Active Not RecruitingNCT05794906
What this trial is testing

Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

Who this might be right for
Biochemically Recurrent Prostate Cancer
Bayer 985
Testing effectiveness (Phase 2)Study completedNCT03617588
What this trial is testing

68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer

Who this might be right for
Prostate Cancer
Theragnostics Ltd 49
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05778097
What this trial is testing

Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)

Who this might be right for
Prostate CancerBiochemical RecurrenceHigh Risk
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 103
Large-scale testing (Phase 3)Looking for participantsNCT04242017
What this trial is testing

Long-term Better Than Short-term ADT With Salvage RT

Who this might be right for
Prostate Cancer
Universitaire Ziekenhuizen KU Leuven 394
Early research (Phase 1)Active Not RecruitingNCT06555796
What this trial is testing

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Who this might be right for
Prostate CancerHigh-risk Biochemical RecurrenceHigh Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer+1 more
Amgen 50
Not applicableNot Yet RecruitingNCT07483658
What this trial is testing

Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

Who this might be right for
Reccurent/Metastatic Solid Tumor DiseaseProstate Cancer (Post Prostatectomy)Prostate Cancer+3 more
CHU de Quebec-Universite Laval 434
Not applicableApproved For MarketingNCT04452136
What this trial is testing

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

Who this might be right for
Prostatic NeoplasmsProstatic DiseasesProstate Cancer+2 more
Jeanne Link